Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects

Texas Heart Institute Journal

Volumn 35, Issue 3, 2008, Pages 256-261

  Mehta, Puja K ^a   Simpson, Leo ^d   Lee, Eva K ^c   Lyle, Teresa A ^a   McConnell, Michael E ^b   Book, Wendy M ^a,e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Emory Sibley Heart Center

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^d ST LUKE S EPISCOPAL HOSPITAL   (United States)

^e Adult Congenital Cardiac Program   (United States)

Author keywords

Antihypertensive agents administration dosage therapeutic use; Bosentan; Eisenmenger complex complications drug therapy mortality physiopathology; Endothelin 1 antagonists inhibitors; Exercise tolerance drug effects; Heart defects congenital

Indexed keywords

BOSENTAN; SITAXSENTAN;

ADULT; ARTICLE; ATRIOVENTRICULAR CANAL; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DRUG DOSE INCREASE; EISENMENGER COMPLEX; EXERCISE TOLERANCE; FEMALE; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; LUNG ARTERY PRESSURE; MALE; OXYGEN SATURATION; PATENT DUCTUS ARTERIOSUS;

ADMINISTRATION, ORAL; ADULT; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EISENMENGER COMPLEX; EXERCISE TEST; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; OXYGEN; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RETROSPECTIVE STUDIES; SULFONAMIDES; THIOPHENES;

EID: 56049125780     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger syndrome in adults. Ann Intern Med 1998;128(9):745-55.
2. Granton JT, Rabinovitch M. Pulmonary arterial hypertension in congenital heart disease. Cardiol Clin 2002;20(3):441-57, vii.
3. Curran WD, Akindipe O, Staples ED, Baz MA. Lung transplantation for primary pulmonary hypertension and Eisenmenger's syndrome. J Cardiovasc Nurs 2005;20(2):124-32.
4. Bowyer JJ, Busst CM, Denison DM, Shinebourne EA. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 1986;55(4):385-90.
5. Sandoval J, Aguirre JS, Pulido T, Martinez-Guerra ML, Santos E, Alvarado P, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001;164(9):1682-7.
6. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351(14):1425-36.
7. Mehta S. Drug therapy for pulmonary arterial hypertension: what's on the menu today? Chest 2003;124(6):2045-9.
8. Lacassie HJ, Germain AM, Valdes G, Fernandez MS, Allamand F, Lopez H. Management of Eisenmenger syndrome in pregnancy with sildenafil and L-arginine. Obstet Gynecol 2004;103(5 Pt 2):1118-20.
9. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108(17):2066-9.
10. Benigni A, Remuzzi G. Endothelin antagonists. Lancet 1999;353(9147):133- 8.
11. Schiffrin EL. State-of-the-Art lecture. Role of endothelin-1 in hypertension. Hypertension 1999;34(4 Pt 2):876-81.
12. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332(6163):411-5.
13. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99(14):1858-65.
14. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000;102(19):2434-40.
15. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al.; STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169(4):441-7.
16. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121(6):1860-8.
17. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al.; BREATHE-5 Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114(1):48-54.
18. Schulze-Neick I, Gilbert N, Ewert R, Witt C, Gruenig E, Enke B, et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J 2005;150(4):716.
19. Christensen DD, McConnell ME, Book WM, Mahle WT. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol 2004;94(2):261-3.
20. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358(9288):1119-23.
21. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension [published erratum appears in N Engl J Med 2002;346(16):1258]. N Engl J Med 2002;346(12):896-903.
22. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124(1):247-54.
23. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart 2005;91(11):1447-52.
24. Gatzoulis MA, Rogers P, Li W, Harries C, Cramer D, Ward S, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol 2005;98(1):147-51.